Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-• IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

- **PEARLS/KEYNOTE-091** Investigators
- Lancet Oncol 2022; 23: 1274–86


Mary O'Brien*, Luis Paz-Ares*, Sandrine Marreaud, Urania Dafni, Kersti Oselin, Libor Havel, Emilio Esteban, Dolores Isla, Alex Martinez-Marti, Martin Faehling, Masahiro Tsuboi, Jong-Seok Lee, Kazuhiko Nakagawa, Jing Yang, Ayman Samkari, Steven M Keller, Murielle Mauer, Nitish Jha, Rolf Stahel, Benjamin Besse⁺, Solange Peters⁺, on behalf of the EORTC-1416-LCG/ETOP 8-15 –

			-	
 Eligibility for Registration Confirmed stage IB (T ≥4 cm), II, or IIIA NSCLC per AJCC v7 Complete surgical resection with pogative marging (P0) 	 ECOG PS 0 or 1 Adjuvant chemotherapy 	Pembrolizumab 200 mg Q3W for ≤18 administrations (~1 yr)		 Secondary End Points DFS in the PD-L1 TPS ≥1% populat OS in the overall, PD-L1 TPS ≥50% PD-L1 TPS ≥1% populations
negative margins (R0) Provision of tumor tissue for PD-L1 testing Stratification Eactors: disease stage (IB vs. II vs. IIIA)	 Considered for stage IB (T ≥4 cm) disease Strongly recommended for stage II and IIIA disease Limited to ≤4 cycles 	1:1 Placebo Q3W for ≤18 administrations (~1 yr)		 Lung cancer-specific survival in the overall population Safety


Stratification Factors: disease stage (IB vs II vs IIIA), PD-L1 TPS (<1% vs 1-49% vs ≥50%), adjuvant chemotherapy (yes vs no), geographic region (Asia vs E. Europe vs W. Europe vs ROW)

	Overall		PD-L1 TPS ≥50%			Overall		PD-L1 TPS ≥50%	
Characteristic	ActicPembroPlaceboPembroPlaceboCharacteristic(N = 590)(N = 587)(N = 168)(N = 165)Characteristic	Characteristic	Pembro (N = 590)	Placebo (N = 587)	Pembro (N = 168)	Placebo (N = 165)			
Age, median (range), y	65.0 (31-87)	65.0 (37-85)	64.5 (38-82)	65.0 (37-85)	Current/former smoker	85.3%	88.8%	91.7%	92.1%
Male sex	68.0%	68.7%	72.0%	70.3%	Nonsquamous histology	67.5%	61.8%	61.3%	63.6%
Geographic region					Nonsquarious histology	07.070	01.070	01.070	00.070
Asia	18.0%	17.9%	17.3%	17.6%	Received adjuvant	85.8%	85.9%	85.1%	85.5%
Eastern Europe	19.7%	19.3%	18.5%	18.2%	chemotherapy				
Western Europe	51.4%	51.3%	53.6%	53.9%	Pathologic stage ^a				
Rest of world	11.0%	11.6%	10.7%	10.3%	IB	14.2%	14.5%	12.5%	13.3%
ECOG PS 1	35.6%	41.6%	31.0%	38.8%	I	55.8%	57.6%	56.5%	56.4%
					IIIA	30.0%	27.6%	31.0%	30.3%
					EGFR mutation ^b	6.6%	5.8%	3.6%	3.0%
participants in the place	o arm had stags	N/ disease: neit	har had TDS >50	00/	ALK translocation ^c	1.2%	1.2%	1.8%	0.0%

^a2 (0.3%) participants in the placebo arm had stage IV disease; neither had TPS ≥50%. ^bEGFR mutation status was unknown for 56.9% of participants (59.5% with TPS ≥50%). ^cALK translocation status was unknown for 63.5% of participants (65.2% with TPS ≥50%).



PEARLS/KEYNOTE-091: Primary Results From the Protocol-Specified Second Interim Analysis (IA2)



- DFS benefit generally consistent across most protocol-specified subgroups, including PD-L1 TPS <1% (HR 0.78, 95% CI 0.58-1.03) and 1-49% (HR 0.67, 95% CI 0.48-0.92)
- Overall safety profile generally as expected for pembrolizumab monotherapy •

Median follow-up, defined as time from randomization to the IA2 data cutoff date of September 20, 2021, was 35.6 mo (range, 16.5-68.0). Paz-Ares L et al. Ann Oncol 2022; 2022-4;33:451-453 (Abstr VP3-2022).

0

Objective: Explore the Potential Impact of the Type of Surgical Resection, Baseline Disease Burden, and Use of Adjuvant Chemotherapy on DFS at IA2

	Pembro (N = 590)	Placebo (N = 587)		Pembro (N = 590)	Placebo (N = 587)		
Type of surgery, n (%)		Received adjuvant cl	nemotherapy		Type of adjuvant p	a
Bilobectomy	47 (8.0)	45 (7.7)	No, n (%)	84 (14.2)	83 (14.1)	Carboplatin-based	
Lobectomy	461 (78.1)	464 (79.0)	Reason for not rec	on for not receiving, n			
Pneumonectomy	65 (11.0)	62 (10.6)	Participant	20	20	Cisplatin-based only	
Other	17 (2.9)	16 (2.7)	refused	36	30	Carboplatin- and	
pN status, n (%)	()		Physician decision ^a	46	47	cisplatin-based Adjuvant regimen,	n
0	233 (39.5)	257 (43.8)	Unknown	2	6	Carboplatin +	
1	233 (39.5)	223 (38.0)	Disease stage in th	isease stage in those who did not receive, n	paclitaxel		
2	124 (21.0)	107 (18.2)	IB	24	30	Carboplatin +	
Tumor size, n (%)			II	48	43	vinorelbine	
≤4 cm	252 (42.7)	239 (40.7)	IIIA	12	10	Cisplatin + gemcitabine	
>4 cm	337 (57.1)	348 (59.3)	Yes, n (%)	506 (85.8)	504 (85.9)	Cisplatin +	
Missing	1 (0.2)	0				vinorelbine	
_			1-2 cycles	35 (5.9)	32 (5.5)	Other	
			3-4 cycles	471 (79.8)	472 (80.4)		


^aBased on unfavorable benefit/risk profile for the individual participant. Data cutoff date: September 20, 2021.



Results: DFS in Subgroups Related to Surgical Resection, Disease Burden, and Use of Adjuvant Chemotherapy

Subgroup	No. Events/ No. Participants		Hazard Ratio	(95% CI)
Overall	472/1177			0.76 (0.63-0.91)
Type of surgery				
Bilobectomy	33/92			0.85 (0.43-1.69)
Lobectomy	374/925			0.78 (0.64-0.96)
Pneumonectomy	50/127	-		0.71 (0.40-1.24)
pN status				
0	161/490			0.63 (0.46-0.86)
1	179/456			0.77 (0.57-1.03)
2	132/231	-+	-	1.00 (0.71-1.41)
Tumor size				
≤4 cm	200/491			0.91 (0.69-1.20)
>4 cm	271/685			0.70 (0.55-0.89)
	0.2	0.5 1.0	2.0	5.0
		Pembrolizumab Better	Placebo Better	

95% CIs of all subgroups overlapped the 95% CI of the overall population and included the overall HR of 0.76. Data cutoff date: September 20, 2021. DFS was defined as time from randomization to locoregional or metastatic recurrence assessed per RECIST v1.1 by investigator review, appearance of second NSCLC primary or other malignancy, or death from any cause, whichever occurred first. DFS was not analyzed in subgroups of <50 participants in the overall population. Receipt of adjuvant chemotherapy was a protocol-specified subgroup; all other subgroups are exploratory.



Conclusions

- adjuvant chemotherapy
 - lack of power and lack of multiplicity adjustment
- recommended, adjuvant chemotherapy

In this exploratory analysis, pembrolizumab generally improved DFS regardless of the type of surgical resection, degree of lymph node involvement, tumor size, and type and extent of

- Exploratory subgroup analysis results should be interpreted with caution due to the

 Together with the overall efficacy and safety findings, these data support the benefit of adjuvant pembrolizumab for stage IB (T \geq 4 cm) to IIIA NSCLC following complete resection and, if

Thankyou